Cefpodoxime Oral Suspension
Cefpodoxime Proxetil IP eq. to Cefpodoxime 50mg/5ml Oral Suspension · Antibiotics, Pediatric Care, Infectious Diseases
WHO-GMP
DCGI Approved
Baddi, HP
Active Pharma Composition
SUSPENSION PRESENTATION (50mg):
Each 5 ml contains:
Cefpodoxime Proxetil IP eq. to Cefpodoxime
50 mg
Flavoured Suspension Base
q.s.
SUSPENSION PRESENTATION (100mg):
Each 5 ml contains:
Cefpodoxime Proxetil IP eq. to Cefpodoxime
100 mg
Flavoured Suspension Base
q.s.
Product Data Sheet
Segments & Ranges
Suspensions / Oral Liquids
Dosage Form
Oral Suspension
Pharma Class
Antibiotics / Pediatric Care / Infectious Diseases
Pack Sizes
30 ml / 60 ml
Storage Condition
Store below 30°C in a cool, dry place. Protect from direct sunlight. Do not freeze. Shake well before every use.
Stability / Shelf Life
24 Months
Manufacturing Location
Baddi, Himachal Pradesh
Compliance
DCGI Approved / Schedule M
Available Strengths
Cefpodoxime 50mg/5ml | Cefpodoxime 100mg/5ml
Flavor Options
Mango and Mixed Fruit — preferred for pediatric suspensions
Pack Options
30ml & 60ml — sticker label, metallic label, drip-off embossed carton, measuring cap, printed cap, with/without carton
Batch Size
5,000 to 2,00,000+ Units
Schedule M Compliant
Private Label Ready
Pan-India Dispatch
WHO-GMP
ISO 9001:2015
GLP Certified
DCGI Approved
Schedule M
Product Profile
Cefpodoxime Proxetil Oral Suspension is a third-generation cephalosporin antibiotic indicated for various bacterial infections. As a premier WHO-GMP certified pharmaceutical manufacturer in Baddi, Saar Biotech manufactures this suspension with validated API quality control.
DCGI Approved
Comprehensive documentation and CDSCO support for rapid market entry in India.
Fast Turnaround
30-45 days lead time for new batches with state-of-the-art logistics.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
Description & Therapeutic Class
Cefpodoxime Oral Suspension belongs to the Suspensions category within the Antibiotics, Pediatric Care, and Infectious Diseases therapeutic segments.
Saar Biotech manufactures this suspension from our manufacturing facility in Baddi.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
The Saar Biotech Advantage
At Saar Biotech, we manufacture Cefpodoxime Suspension using a controlled oral suspension manufacturing process that ensures dose uniformity and palatability.
- API Uniformity: Cefpodoxime is uniformly suspended for consistent dosing.
- Taste Masking: Mango and mixed fruit flavours mask the bitter taste.
- pH and Stability Management: The active remains chemically stable for 24 months.
- 30ml and 60ml Pack Coverage: Suitable for pediatric and adult treatment courses.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
Key Indications & Clinical Use
This suspension is manufactured and supplied by Saar Biotech for the following established clinical indications:
- Acute Otitis Media: Middle ear infections
- Pharyngitis & Tonsillitis: Streptococcal infections
- Bronchitis: Acute bacterial bronchitis
- Sinusitis: Acute bacterial sinusitis
- Urinary Tract Infections: Cystitis, pyelonephritis
Schedule H — Requires valid medical prescription.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
Mechanism of Action & Manufacturing Integrity
Cefpodoxime inhibits bacterial cell wall synthesis, causing cell lysis and death.
Manufacturing Integrity
- Suspension Uniformity: Cefpodoxime is uniformly suspended for consistent dosing.
- pH Stability: The suspension vehicle is pH-buffered to maintain active stability.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
B2B & Contract Manufacturing Details
Saar Biotech provides Third-Party Manufacturing for Cefpodoxime Suspension from our oral suspension manufacturing facility in Baddi, Himachal Pradesh.
- Facility: Oral suspension manufacturing area with controlled processing, automated bottle filling, capping, labelling, and carton packing lines.
- Capacity: Scalable from brand-entry launches to large commercial batches.
- Quality Lab: In-house GLP-certified lab with HPLC assay, pH, viscosity, MLT, and fill volume checks.
- Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
- Packaging: 30ml and 60ml PET or dark amber bottles; sticker label, metallic label, measuring cup, printed cap.
- MOQ: Starting at 5,000–10,000 units per SKU.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
Storage & Handling Guidelines
- Warehouse Conditions: Store below 30°C in a cool, dry environment. Do not freeze.
- Shake Well Before Every Dose: Critical for uniform API distribution.
- Measuring Cup Use: A calibrated measuring cup ensures accurate dosing.
- Light Protection: Dark amber bottles and outer cartons protect from light-induced degradation.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
Quality Control & Compliance
Every commercial batch is quarantined until it passes a comprehensive analytical release protocol:
- HPLC Assay: Quantification of Cefpodoxime content.
- Suspension Uniformity: Sediment behaviour and re-dispersibility testing.
- pH & Viscosity Testing: Suspension stability monitoring.
- Microbial Limit Testing (MLT): IP-compliant microbiological testing.
- Certificate of Analysis (COA): Issued with every B2B batch.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
Safety Profile & Precautions
- Allergic Reactions: Risk of hypersensitivity in penicillin-allergic patients.
- Gastrointestinal Effects: Diarrhoea, nausea, vomiting.
- Contraindications: Known hypersensitivity to cephalosporins.
For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Cefpodoxime Suspension, please use the B2B enquiry form below.
Pan-India Supply & Contract Manufacturing
Batch Lead Time
30-45 Days (Domestic)
B2B Services
Contract & Third-Party
Compliance
DCGI & Schedule M Standards
Medical Intelligence
Clinical Q&A for Cefpodoxime Oral Suspension
Technical data on bioavailability, pediatric dosing protocols, and therapeutic efficacy for healthcare professionals.
What are the clinical indications for Cefpodoxime Oral Suspension?
Cefpodoxime Oral Suspension is indicated for the treatment of infections caused by susceptible organisms, including acute otitis media, pharyngitis, tonsillitis, bronchitis, sinusitis, and urinary tract infections. It is a third-generation cephalosporin with broad-spectrum activity.
How does Cefpodoxime work as an antibiotic?
Cefpodoxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, preventing cross-linking of peptidoglycan and causing bacterial cell lysis. It has enhanced activity against Gram-positive and Gram-negative bacteria compared to earlier cephalosporins.
What is the standard dosing protocol?
The standard dose for children is 5 to 8 mg/kg/day, administered in two divided doses. The suspension should be shaken well before each use. Treatment duration is usually 5 to 10 days.
What are the key contraindications and precautions?
Cefpodoxime is contraindicated in patients with known hypersensitivity to cephalosporins. Caution is advised in patients with penicillin allergy, renal impairment, and gastrointestinal disease.
What are the common side effects?
Common side effects may include diarrhoea, nausea, abdominal pain, headache, and vaginitis. Most of these are mild and transient.
Manufacturing Support
B2B Manufacturing Guide for Cefpodoxime Oral Suspension
Detailed insights on MOQs, lead times, and regulatory support for contractmanufacturing partners.
What pack sizes and packaging options are available for Cefpodoxime Suspension?
Saar Biotech manufactures Cefpodoxime Suspension in 30 ml and 60 ml bottle formats. Both 50mg/5ml and 100mg/5ml strengths are available. Packaging options include: sticker label, metallic label, drip-off brand embossed carton, measuring cap, printed cap, company-logo printed PP cap, with-carton or without-carton supply.
What is the MOQ for Cefpodoxime Suspension?
Standard MOQ ranges from 5,000 to 10,000 units per SKU, depending on bottle size and strength.
What analytical tests are performed on every manufacturing batch?
Every batch undergoes HPLC Assay confirming Cefpodoxime content, suspension uniformity testing, pH and viscosity testing, and Microbial Limit Testing (MLT). A Certificate of Analysis (COA) is issued.
What is the turnaround time for a new order?
Initial third-party production typically requires 30 to 45 working days following packaging confirmation. Repeat orders are fulfilled in 20–25 working days.
Do you offer private labelling and packaging design?
Yes, our in-house design team provides end-to-end support for private label packaging, including mono-cartons, labels, and promotional materials compliant with regulatory guidelines.
Discover More
Related Health Solutions
Explore other trusted medicines that help treat similar health conditions.
